Assessment of the Rate of Adherence to International Guidelines for Androgen Deprivation Therapy with External-beam Radiation Therapy: A Population-based Study

European Urology

Volumn 70, Issue 3, 2016, Pages 429-435

  Dell'Oglio, Paolo ^a,b   Abou Haidar, Hiba ^a   Leyh Bannurah, Sami Ramzi ^a,c   Tian, Zhe ^a,d   Larcher, Alessandro ^b   Gandaglia, Giorgio ^b   Fossati, Nicola ^b   Shariat, Shahrokh F ^e   Capitanio, Umberto ^b   Briganti, Alberto ^b   Montorsi, Francesco ^b   Graefen, Markus ^c   Saad, Fred ^a   Karakiewicz, Pierre I ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d MCGILL UNIVERSITY   (Canada)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

High risk prostate cancer; Locally advanced prostate cancer; RT ADT; SEER Medicare

Indexed keywords

ADVANCED CANCER; AGE; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER STAGING; CARDIOVASCULAR DISEASE; CHARLSON COMORBIDITY INDEX; CLINICAL ASSESSMENT TOOL; CLINICAL EVALUATION; EXTERNAL BEAM RADIOTHERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; MARRIAGE; MEDICARE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OUTCOME ASSESSMENT; POPULATION DENSITY; POPULATION RESEARCH; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROTOCOL COMPLIANCE; STATISTICAL ANALYSIS; UNITED STATES; VERY ELDERLY; WORLD HEALTH ORGANIZATION GRADING SYSTEM; ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; AGONISTS; ANCESTRY GROUP; CANCER GRADING; CANCER REGISTRY; COMORBIDITY; PATHOLOGY; PROSTATE TUMOR; RADIOTHERAPY; SECONDARY; STATISTICS AND NUMERICAL DATA;

ANDROGEN RECEPTOR ANTAGONIST; ANTINEOPLASTIC AGENT; GONADORELIN;

ADENOCARCINOMA; AGE FACTORS; AGED; AGED, 80 AND OVER; ANDROGEN RECEPTOR ANTAGONISTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COMORBIDITY; CONTINENTAL POPULATION GROUPS; GONADOTROPIN-RELEASING HORMONE; GUIDELINE ADHERENCE; HUMANS; MALE; MARITAL STATUS; MEDICARE; NEOPLASM GRADING; NEOPLASM STAGING; POPULATION DENSITY; PRACTICE GUIDELINES AS TOPIC; PROSTATIC NEOPLASMS; RADIOTHERAPY; SEER PROGRAM; UNITED STATES;

EID: 84959276918     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2016.02.057     Document Type: Article

References (30)

1. ®). Prostate cancer, version 1.2015. National Comprehensive Cancer Network Web site. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Updated 2015.
2. [2] Shao, Y.H., Demissie, K., Shih, W., et al. Contemporary risk profile of prostate cancer in the United States. J Natl Cancer Inst 101 (2009), 1280–1283.
3. [3] Mottet N, Bellmunt J, Briers E, et al. Guidelines on prostate cancer. European Association of Urology Web site. http://uroweb.org/wp-content/uploads/09-Prostate-Cancer_LR.pdf. Updated 2015.
4. [4] Scherr, D., Swindle, P.W., Scardino, P.T., National Comprehensive Cancer Network. National Comprehensive Cancer Network guidelines for the management of prostate cancer. Urology 61 (2003), 14–24.
5. [5] Aus, G., Abbou, C.C., Heidenreich, A., et al. Guidelines on prostate cancer. 2003, European Association of Urology, Arnhem, The Netherlands.
6. [6] NCCN clinical practice guidelines in oncology. Prostate cancer. 2007, National Comprehensive Cancer Network, Fort Washington, PA.
7. [7] Heidenreich, A., Aus, G., Bolla, M., et al. EAU guidelines on prostate cancer. Eur Urol 53 (2008), 68–80.
8. [8] Warren, J.L., Klabunde, C.N., Schrag, D., Bach, P.B., Riley, G.F., Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 40 (2002), IV–IV3.
9. [9] Klabunde, C.N., Potosky, A.L., Legler, J.M., Warren, J.L., Development of a comorbidity index using physician claims data. J Clin Epidemiol 53 (2000), 1258–1267.
10. [10] Gandaglia, G., Sun, M., Popa, I., et al. Cardiovascular mortality in patients with metastatic prostate cancer exposed to androgen deprivation therapy: a population-based study. Clin Genitourinary Cancer 13 (2015), e123–e130.
11. [11] Bolla, M., Gonzalez, D., Warde, P., et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337 (1997), 295–300.
12. [12] Pilepich, M.V., Caplan, R., Byhardt, R.W., et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85–31. J Clin Oncol 15 (1997), 1013–1021.
13. [13] Bolla, M., Collette, L., Blank, L., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360 (2002), 103–106.
14. [14] Pilepich, M.V., Winter, K., Lawton, C.A., et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma–long-term results of phase III RTOG 85–31. Int J Radiat Oncol Biol Phys 61 (2005), 1285–1290.
15. [15] D'Amico, A.V., Chen, M.H., Renshaw, A.A., Loffredo, M., Kantoff, P.W., Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA 299 (2008), 289–295.
16. [16] Nguyen, P.L., Alibhai, S.M., Basaria, S., et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol 67 (2015), 825–836.
17. [17] D'Amico, A.V., Denham, J.W., Crook, J., et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 25 (2007), 2420–2425.
18. [18] Keating, N.L., O'Malley, A.J., Smith, M.R., Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24 (2006), 4448–4456.
19. [19] Lowrance, W.T., Elkin, E.B., Yee, D.S., et al. Locally advanced prostate cancer: a population-based study of treatment patterns. BJU Int 109 (2012), 1309–1314.
20. [20] Kim, M.M., Hoffman, K.E., Levy, L.B., et al. Improvement in prostate cancer survival over time: a 20-year analysis. Cancer J 18 (2012), 1–8.
21. [21] Bekelman, J.E., Mitra, N., Handorf, E.A., et al. Effectiveness of androgen-deprivation therapy and radiotherapy for older men with locally advanced prostate cancer. J Clin Oncol 33 (2015), 716–722.
22. [22] Abdollah, F., Abdo, A., Sun, M., et al. Pelvic lymph node dissection for prostate cancer: adherence and accuracy of the recent guidelines. Int J Urol 20 (2013), 405–410.
23. [23] Aizer, A.A., Paly, J.J., Zietman, A.L., et al. Models of care and NCCN guideline adherence in very-low-risk prostate cancer. J Natl Compr Canc Netw 11 (2013), 1364–1372.
24. [24] Makarov, D.V., Desai, R.A., Yu, J.B., et al. The population level prevalence and correlates of appropriate and inappropriate imaging to stage incident prostate cancer in the medicare population. J Urol 187 (2012), 97–102.
25. [25] Bagaria, S.P., Ashman, J.B., Daugherty, L.C., Gray, R.J., Wasif, N., Compliance with National Comprehensive Cancer Network guidelines in the use of radiation therapy for extremity and superficial trunk soft tissue sarcoma in the United States. J Surg Oncol 109 (2014), 633–638.
26. [26] Thuret, R., Sun, M., Lughezzani, G., et al. A contemporary population-based assessment of the rate of lymph node dissection for penile carcinoma. Ann Surg Oncol 18 (2011), 439–446.
27. [27] Shirvani, S.M., Pan, I.W., Buchholz, T.A., et al. Impact of evidence-based clinical guidelines on the adoption of postmastectomy radiation in older women. Cancer 117 (2011), 4595–4605.
28. [28] Korman, H., Lanni, T. Jr., Shah, C., et al. Impact of a prostate multidisciplinary clinic program on patient treatment decisions and on adherence to NCCN guidelines: the William Beaumont Hospital experience. Am J Clin Oncol 36 (2013), 121–125.
29. [29] Gomella, L.G., Lin, J., Hoffman-Censits, J., et al. Enhancing prostate cancer care through the multidisciplinary clinic approach: a 15-year experience. J Oncol Pract 6 (2010), e5–e10.
30. [30] Wong, Y.N., Mitra, N., Hudes, G., et al. Survival associated with treatment vs observation of localized prostate cancer in elderly men. JAMA 296 (2006), 2683–2693.